Disculpa, pero esta entrada está disponible sólo en Inglés Estadounidense. For the sake of viewer convenience, the content is shown below in the alternative language. You may click the link to switch the active language.
The current guideline needs revision covering the latest developments with regard to requirements for clinical trials in partial and non-responders with MDD and options of targeting new functional domains. In addition, it may include requirements to increase depression clinical trials efficiency.